Quarterly ResultMay 6, 2026, 04:15 PM
Quanterix Q1 Revenue +20% to $36.4M; Net Loss Narrows
AI Summary
Quanterix Corporation reported a 20% increase in first-quarter 2026 revenue to $36.4 million, with a narrowed GAAP net loss of $17.5 million. The company is prioritizing its product roadmap and investing in commercial effectiveness, particularly in its rapidly growing Alzheimer's diagnostics business. Quanterix reaffirmed its full-year 2026 guidance, expecting revenues of $169-$174 million and anticipating cash flow breakeven in the second half of the year.
Key Highlights
- Q1 2026 revenue increased 20% to $36.4 million from $30.3 million in Q1 2025.
- GAAP net loss narrowed to $17.5 million ($0.37 per share) from $20.5 million ($0.53 per share) in Q1 2025.
- Adjusted EBITDA loss improved to $9.8 million from $11.3 million in the prior year.
- Ended Q1 with $102.6 million in cash, cash equivalents, and marketable securities.
- Reaffirmed 2026 revenue guidance of $169 million to $174 million.
- Anticipates achieving cash flow breakeven in the second half of 2026.
- Announced collaborations with Tempus AI and Life Line Screening for Alzheimer's diagnostics.
- Launched new Simoa® assays and Akoya PhenoImager™ HT cancer panels.